Therapeutic Goods (Poisons Standard) (COVID-19 Treatment - Gilead) (Remdesivir) Labelling Exemption 2022
Published
Related content
- Therapeutic Goods (Poisons Standard) (COVID-19 Treatment - Gilead) (Remdesivir) Labelling Exemption 2021This labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.
- Therapeutic Goods (Poisons Standard) (COVID-19 Vaccine - Moderna) (Elasomeran) Labelling Exemption 2022This labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.
- Therapeutic Goods (Poisons Standard) (COVID-19 Treatment - GlaxoSmithKline) (Sotrovimab) Labelling Exemption 2022This labelling exemption is granted under section 1.5.5 of Part 2 of the current Poisons Standard.